Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b

Neurological Sciences

Volumn 30, Issue 1, 2009, Pages 21-31

  Lazzaro, Carlo ^a   Bianchi, Cosetta ^b   Peracino, Lucia ^b   Zacchetti, Paola ^b   Uccelli, Antonio ^c  

^a Studio di Economia Sanitaria   (Italy)

^b Bayer SpA Italy   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

CIS; Cost utility analysis; Interferon 1b; MS

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG RESPONSE; DRUG WITHDRAWAL; EARLY INTERVENTION; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HUMAN; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; THERAPY DELAY;

ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; EPIDEMIOLOGIC STUDIES; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INTERFERON-BETA; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATIONAL HEALTH PROGRAMS;

EID: 60449099240     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0015-0     Document Type: Article

References (52)

1. McFarland HF, Martin R (2007) Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 8:913-919
2. Amato MP, Battaglia MA, Caputo D et al M for the Mu S. I. C. Study Group (2002) The cost of multiple sclerosis: A cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249:152-163
3. Miller DH (2003) Commentary: Evaluating disease modifying treatments in multiple sclerosis. BMJ 326:526-527
4. Kobelt G, Berg J, Lindgren P et al (2006) Costs and quality of multiple sclerosis in Italy. Eur J Health Econ 7:545-554
5. Jacobs LD, Beck RW, Simon JH, The Champs StudyGroup (2000) Intramuscular interferon beta 1-a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904
6. Filippi M, Rovaris M, Inglese M et al (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet 364:1463-1464
7. Kappos L, Polman CH, Freedman MS et al for the BENEFIT Study Group (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242-1249
8. Chilcott J, McCabe C, Tappenden P et al on behalf of the Cost Effectiveness of Multiple Sclerosis Therapies Study Group (2003) Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 326:522-526
9. Attena F (2004) Epidemiologia e valutazione degli interventi sanitari. Piccin, Padova, pp 151-190
10. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
11. Tintoré M, Rovira A, Río J et al (2003) New diagnostic criteria for multiple sclerosis: Application in first demyelinating episode. Neurology 60:27-30
12. Young TA (2005) Estimating mean total costs in the presence of censoring. A comparative assessment of methods. Pharmacoeconomics 23:1229-1242
13. Pfeifer PE, Bang H (2005) Non-parametric estimation of mean customer lifetime value. Journal of Interactive Marketing. doi: 10.1002/dir.20049
14. Glick HA, Doshi JA, Sonnad SA, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press, Oxford, pp 21-22; 115-132
15. Rice GPA (2001) The use of betaseron in treatment of MS. ENS, Berlin
16. Compston A, McDonald I, Noseworthy J, Lassmann H, Miller D, Smith K, Wekerle H, Confavreux C (2005) McAlpine's multiple sclerosis, 4th edn. Elsevier, Amsterdam
17. Associazione Italiana Sclerosi Multipla (2000) Sclerosi multipla in Italia. Associazione Italiana Sclerosi Multipla, Genova, p 9
18. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452
19. Holmes BA, Madgwick T, Bates D (1995) The cost of MS. Br J Med Econ 8:181-193
20. Kobelt G, Jönsson L, Fredrickson S et al (2001) Cost-utility analysis of interferon β-1b in the treatment of different types of multiple sclerosis. Stockholm School of Economics, SSE/EFI Working Papers on Economics and Finance, Stockholm, No 459
21. Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
22. Drummond MF, Schulper MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford
23. Pittock SJ, Mayr WT, McClelland RL et al (2004) Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62:601-606
24. Ministero della Sanità (1999) Nomenclatore tariffario delle protesi. Elenco N. 1: Nomenclatore tariffario delle prestazioni sanitarie protesiche. Ministero della Sanità, Roma
25. Ministero della Sanità (1996) Decreto ministeriale n. 150 del 22 Luglio 1996. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe. Supplemento ordinario alla Gazzetta Ufficiale n. 216 del 14 Settembre 1996, Serie generale. Istituto Poligrafico e Zecca di Stato, Roma
26. Presidente della Repubblica (2000) Decreto del Presidente della Repubblica 28 luglio 2000, n. 270. Regolamento di esecuzione dell'accordo collettivo nazionale per la disciplina dei rapporti con i medici di medicina generale. Supplemento ordinario n. 165/L alla Gazzetta Ufficiale n. 230 del 2 Ottobre 2000, Serie Generale. Istituto Poligrafico e Zecca dello Stato, Roma
27. Conferenza Permanente per i Rapporti tra lo Stato le Regioni e le Province Autonome di Trento e Bolzano (2005) Tariffa Unica Convenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per l'anno 2006. Available via http://www.ministerosalute.it. Accessed 25 Jun 2007
28. Schering SpA (2006) Internal data validation by Hospital Survey Project-TNS Healthcare. Schering S.p.A, Segrate
29. Masson-OEMF (2006) L'Informatore Farmaceutico 2005. Masson-OEMF, Milano
30. Agenzia Italiana del Farmaco, Direzione Generale-Ministero della Salute (2006) Osservatorio Nazionale sull'Impiego dei Medicinali. L'uso dei Farmaci in Italia. Rapporto nazionale anno 2005. Available via http://www.agenziafarmaco.it. Accessed 25 Jun 2007
31. De Pietro C (2005) Gestire il personale nelle aziende sanitarie italiane. McGraw-Hill, Milano, pp 353-365
32. Decision Resources. Cognos Study #3 (2006) Multiple sclerosis. Decision Resources Inc., Waltham, pp 42, 48-50
33. Sistema Statistico Nazionale-Istituto Nazionale di Statistica (2006) Compendio Statistico Italiano. Available via www.istat.it/Anumital/ Astatset/prez.htm. Accessed 4 Feb 2007
34. Attanasio E, Bruzzi P, Capri S et al (1999) Raccomandazioni per la conduzione degli studi di farmacoeconomia: La Guida GISF. Mecosan 29:65-72
35. Pagano M, Gauvreau K (2003) Fondamenti di biostatistica, 2nd edn. Idelson-Gnocchi, Napoli, pp 199-216;361-378
36. Briggs AH, Gray AM (1999) Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess 3:1-134
37. ISIS Research. ISIS Research MS Monitors. US Phase 4 & Europe Phase 13 Results. US and Europe ISIS Research, 2004
38. Good PI (2006) Resampling methods. A practical guide to data analysis, 3rd edn. Birckhäuser, Boston
39. Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, New York
40. Briggs A, Fenn P (1998) Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 7:723-740
41. Briggs AH (2001) Handling uncertainty in economic evaluation. In: Drummond M, McGuire A (eds) Economic evaluation in health care: Merging theory with practice. Oxford University Press, Oxford, pp 172-214
42. Briggs AH, O'Brien BJ, Blackhouse G (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 23:377-401
43. Willan AR, Briggs AH (2006) Statistical analysis of cost-effectiveness data. Wiley, Chichester, pp 51-57
44. Fenwick E, O'Brien BJ, Briggs A (2004) Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 13:405-415
45. Fenwick E, Marshall DA, Levy AR et al (2006) Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 6:52-59
46. O'Hagan A, Stevens JW (2002) The probability of cost-effectiveness. BMC Medical Research Methodology 2. Available via http://www.biomedcentralcom/1471-2288/2/5. Accessed 22 Oct 2007
47. Lin DY, Feuer EJ, Etzioni R et al (1997) Estimating medical costs from incomplete follow-up data. Biometrics 53:419-434
48. Bang H, Tsiatis AA (2000) Estimating medical costs with censored data. Biometrika 87:329-343
49. Russo P, Capone A, Paolillo A et al (2004) Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Invest 24:409-420
50. Flachenecker P, Rieckmann P (2004) Health outcomes in multiple sclerosis. Curr Opin Neurol 17:257-261
51. Messori A, Santarlasci B, Trippoli S et al (2003) Controvalore economico del farmaco e beneficio clinico: Stato dell-arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics-Italian Research Articles 5:53-67
52. Mark DB, Hlatky MA, Califf RM et al (1995) Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332:1418-1424